Continuous positive airway pressure-treated patients' behaviours during the COVID-19 crisis. Issue 4 (2nd November 2020)

• Record Type: Journal Article
• Authors: Pépin, Jean-Louis; Sauvaget, Odile; Borel, Jean Christian; Rolland, Christine; Sapéne, Marc; Amroussia, Ines; Bailly, Sébastien; Tamisier, Renaud
• Is Part Of: ERJ open research. Volume 6:Issue 4(2020)
• Publication Date: 2020-11-02
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00508-2020
• Languages: English
• ISSNs: 2312-0541

Abstract

Obstructive sleep apnoea (OSA) is one of the most prevalent chronic diseases, affecting nearly one billion people worldwide [1]. Continuous positive airway pressure (CPAP) is the first-line therapy for OSA [2], and is currently used by over one million people throughout France. A focus on the OSA population during the COVID-19 outbreak is of particular interest for the following two main reasons. 1) OSA is a multi-morbid disease with up to 70% of patients being obese [3] and exhibiting a high prevalence of cardiometabolic comorbidities. Such a clinical context is expected to be associated with a higher risk of severe forms of COVID-19 and a higher mortality rate [4]. 2) CPAP treatment is considered a high-risk aerosol-generating procedure potentially facilitating viral dispersion into the environment and transmission of infection [5–7]. The #COVID19 pandemic has had limited impact on CPAP use by obstructive sleep apnoea patients. Mainly only those with suspected or proven COVID-19 stopped CPAP use, sometimes without a physician's advice, and were more likely to move to a separate bedroom. https://bit.ly/2RxQDZO